Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the H1N1 Vaccine Market Grown from 2024 to 2025?

There has been a robust growth in the market size of the H1N1 vaccine in the past few years. It’s projected to increase from $3.33 billion in 2024 to $3.55 billion in 2025, experiencing a compound annual growth rate (CAGR) of 6.7%. The growth during the historical era can be associated with factors such as earlier outbreaks of influenza, concerns of global health security, processes related to the development and approval of vaccines, worldwide immunization drives, initiatives to educate the public about health, governmental aid and subsidies, as well as the adaptability of the pharmaceutical industry.

What Growth Rate Is Anticipated for the H1N1 Vaccine Market in the Coming Years?

In the ensuing years, strong expansion is predicted for the H1N1 vaccine market, escalating to $4.79 billion in 2029 with an anticipated compound annual growth rate (CAGR) of 7.8%. Such growth during the projected period can be credited to research on broad-range vaccines, universal vaccine equality efforts, the enhancement of public health resilience, the fortification of global health governance, and the incorporation of H1N1 immunizations into routine vaccinations. Prevailing trends for the forecast period encompass global readiness for pandemics, influenza immunization plans, advancements in vaccine creation, investigations into cross-protection, global health agendas, advancements in vaccine manufacturing technology, the broadening of production capacity, and data scrutiny and oversight.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7881&type=smp

Who Are the Leading Companies in the H1N1 Vaccine Market?

Major companies operating in the H1N1 vaccine market are Sanofi SA, GlaxoSmithKline PLC, CSL Limited, AstraZeneca Inc., Zydus Lifesciences Limited, Merck and Co.Inc., Novavax Inc., Panacea Biotec Ltd., Sinovac Biotech Ltd., Green Cross Corp., Pfizer Inc., Seqirus Ltd., Cipla Inc., Protein Sciences Corporation, Hualan Biological Engineering Inc., Changsheng Bio-Technology Co. Ltd., Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Bio Farma Group, PT Kalbe Farma Tbk, Moderna Inc., CureVac NV, BioNTech SE, Inovio Pharmaceuticals Inc., Vaxart Inc., Altimmune Inc., Dynavax Technologies Corporation, VBI Vaccines Inc., GeoVax Labs Inc.

What Are the Key Drivers of the H1N1 Vaccine Market?

The escalation in spending on research and development endeavors in immunology and vaccine areas is anticipated to catalyze the progression of the H1N1 vaccine market. These facets of science are employed to avert infections and aid in the production of antibodies that combat diseases. Immunology serves an essential role in medical and biological science research, with a primary emphasis on comprehending the ins and outs of the immune system. The H1N1 vaccine, which enhances antibody production and provides immunity against an array of diseases, is a notable illustration. For instance, the National Institutes of Health (NIH), a US institution, divulged in March 2023 that their support in research made the expeditious evolution of mRNA COVID-19 vaccines viable. Fast forwarding to March 2022, the United States administered more than 577 million doses, which projected into an approximated 2.4 million lives preserved, forestalling 17 million hospital admissions. Consequently, the amplified expenditure on research and development in immunology and vaccines is fueling the ascent of the H1N1 vaccine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=7881&type=smp

What Are the Key Market Segments in the H1N1 Vaccine Industry?

The H1N1 vaccine market covered in this report is segmented –

1) By Product Type: Inactivated Vaccine, Live Attenuated Vaccine

2) By Route Of Administration: Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination

3) By End Users: Hospitals, Clinics, Research And Diagnostic Laboratories, Other End Users

Subsegments:

1) By Inactivated Vaccine: Injectable Inactivated Vaccine, Intranasal Inactivated Vaccine

2) By Live Attenuated Vaccine: Injectable Live Attenuated Vaccine, Intranasal Live Attenuated Vaccine

What Are the Latest Trends in the H1N1 Vaccine Market?

The increasing trend of strategic alliances between corporations is becoming more commonplace in the H1N1 (swine flu) vaccination market. Firms within the H1N1 (swine flu) Vaccination market are concentrating on strategic partnerships in order to increase their market presence. For instance, in August 2022, a substantial pharmaceutical firm and Open Orphan affiliate hVIVO entered into a $123 million agreement to develop a new batch of H1N1 influenza challenge virus, which has encouraged both companies’ growth opportunities within this sector.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/h1n1-vaccine-global-market-report

What Are the Key Regional Markets in the H1N1 Vaccine Industry?

North America was the largest region in the H1N1 vaccine market in 2024. The regions covered in the H1N1 vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7881

This Report Delivers Insight On:

1. How big is the h1n1 vaccine market, and how is it changing globally?

2. Who are the major companies in the h1n1 vaccine market, and how are they performing?

3. What are the key opportunities and risks in the h1n1 vaccine market right now?

4. Which products or customer segments are growing the most in the h1n1 vaccine market?

5. What factors are helping or slowing down the growth of the h1n1 vaccine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model